Drugs / BR6001-1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06165237 | Mar → May 2023 | peptic ulcer disease | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BR6001-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06165237 ↗ |